2002 Federal Register / Vol. 90, No. 6 / Friday, January 10, 2025 / Notices 

The National Marine Fisheries Service 

(NMFS) has adopted the Bureau of 

Ocean Energy Management’s Final EIS 

No. 20240137 filed 07/26/2024 with the 

Environmental Protection Agency. The 

NMFS was a cooperating agency on this 

project. Therefore, republication of the 

document is not necessary under 

Section 1506.3(b)(2) of the CEQ 

regulations. 

EIS No. 20250002, Draft, FHWA, HI, 

Honoapi’ilani Highway Improvements 

Project, Comment Period Ends: 02/24/ 

2025, Contact: Paul La Farga 808– 

541–2704. 

EIS No. 20250003, Final, DHS, IBWC, 

GSA, TX, Proposed Modernization of 

the Bridge of the Americas Land Port 

of Entry in El Paso Texas, Review 

Period Ends: 02/10/2025, Contact: 

Karla R. Carmichael 817–996–9475. 

EIS No. 20250004, Draft, USACE, MD, 

Sparrows Point Container Terminal, 

Comment Period Ends: 03/21/2025, 

Contact: Maria N. Teresi 410–962– 

4252. 

EIS No. 20250005, Draft, BLM, OR, 

Bridge Creek Area Allotment 

Management Plans, Comment Period 

Ends: 02/24/2025, Contact: Don Rotell 

541–573–4400. 

EIS No. 20250006, Final, USFWS, OR, 

Elliott State Research Forest Habitat 

Conservation Plan, Review Period 

Ends: 02/10/2025, Contact: Shauna 

Everett 503–231–6949. 

EIS No. 20250007, Final, USFS, ID, 

Land Management Plan for the Nez 

Perce-Clearwater National Forests, 

Review Period Ends: 02/10/2025, 

Contact: Sara Daugherty 208–963– 

4206. 

EIS No. 20250008, Draft, BLM, AZ, 

Ranegras Plains Energy Center Project, 

Comment Period Ends: 02/24/2025, 

Contact: Derek Eysenbach 602–417– 

9505. 

EIS No. 20250009, Draft, NNSA, NM, 

Draft Site-Wide Environmental Impact 

Statement for Continued Operation of 

Los Alamos National Laboratory, 

Comment Period Ends: 03/11/2025, 

Contact: Stephen Hoffman 505–665– 

8980. 

EIS No. 20250010, Draft, FTA, TX, 

Austin Light Rail Phase 1 Project, 

Comment Period Ends: 03/11/2025, 

Contact: Terence Plaskon 817–978– 

0573. 

EIS No. 20250011, Final, TVA, MS, New 

Caledonia Gas Plant Project, Review 

Period Ends: 02/10/2025, Contact: 

Erica McLamb 423–751–8022. 

EIS No. 20250012, Final, OSM, MT, 

Spring Creek Mine, Review Period 

Ends: 02/10/2025, Contact: Marcelo 

Calle 303–236–2929. 

Amended Notice: 

EIS No. 20240148, Draft, APHIS, PRO, 

Outbreak Response Activities for 

Highly Pathogenic Avian Influenza 

Outbreaks in Poultry in the United 

States and U.S. Territories, Comment 

Period Ends: 01/17/2025, Contact: 

Chelsea Bare 515–337–6128. 

Revision to FR Notice published 08/ 

16/2024; APHIS has reopened the 

comment period to end on 01/17/2025. 

Dated: January 6, 2025. 

Mark Austin, 

Acting Director, NEPA Compliance Division, 

Office of Federal Activities. 

[FR Doc. 2025–00363 Filed 1–8–25; 8:45 am] 

BILLING CODE 6560–50–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2025–0003] 

Meeting of the Advisory Committee on 

Immunization Practices 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting and request 

for comment. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC) announces the 

following meeting of the Advisory 

Committee on Immunization Practices 

(ACIP). This meeting is open to the 

public. Time will be available for public 

comment. 

DATES: The meeting will be held on 

February 26, 2025, from 8 a.m. to 5:10 

p.m., EST, February 27, 2025, from 8 

a.m. to 5 p.m., EST, and February 28, 

2025, from 8 a.m. to 11:25 a.m., EST 

(times subject to change; see the ACIP 

website for updates: https://

www.cdc.gov/acip). 

Written comments must be received 

between February 3–17, 2025. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2025– 

0003, by either of the methods listed 

below. CDC does not accept comments 

by email. 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Ms. Stephanie Thomas, ACIP 

Meeting, Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

Mailstop H24–8, Atlanta, Georgia 

30329–4027. Attn: Docket No. CDC– 

2025–0003. 

Instructions: All submissions received 

must include the Agency name and 

docket number. All relevant comments 

received in conformance with the 

https://www.regulations.gov suitability 

policy will be posted without change to 

https://www.regulations.gov, including 

any personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

https://www.regulations.gov. 

The meeting will be webcast live via 

the World Wide Web. The webcast link 

can be found on the ACIP website at 

https://www.cdc.gov/acip. 

FOR FURTHER INFORMATION CONTACT: 

Stephanie Thomas, Committee 

Management Specialist, Advisory 

Committee on Immunization Practices, 

National Center for Immunization and 

Respiratory Diseases, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, Mailstop H24–8, 

Atlanta, Georgia 30329–4027. 

Telephone: (404) 639–8836; Email: 

ACIP@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The Advisory Committee on 

Immunization Practices (ACIP) is 

charged with advising the Director, 

Centers for Disease Control and 

Prevention (CDC), on the use of 

immunizing agents. In addition, under 

42 U.S.C. 1396s, the Committee is 

mandated to establish and periodically 

review and, as appropriate, revise the 

list of vaccines for administration to 

vaccine-eligible children through the 

Vaccines for Children program, along 

with schedules regarding dosing 

interval, dosage, and contraindications 

to administration of vaccines. Further, 

under applicable provisions of the 

Affordable Care Act and section 2713 of 

the Public Health Service Act, 

immunization recommendations of 

ACIP that have been approved by the 

Director, CDC, and appear on CDC 

immunization schedules generally must 

be covered by applicable health plans. 

Matters to be Considered: The agenda 

will include discussions on 

chikungunya vaccines, COVID–19 

vaccines, cytomegalovirus (CMV) 

vaccine, Human papillomavirus (HPV) 

vaccines, influenza vaccines, 

meningococcal vaccines, mpox 

vaccines, pneumococcal vaccines, 

Respiratory Syncytial Virus (RSV) 

vaccines for adults, RSV vaccines for 

maternal and pediatric populations, and 

Lyme disease. Recommendation votes 

are scheduled for meningococcal 

vaccines, chikungunya vaccines, 

influenza vaccines, and RSV vaccines 

for adults. Vaccines for Children (VFC) 

votes are scheduled for influenza and 

meningococcal vaccines. Agenda items 


khammond on DSK9W7S144PROD with NOTICES
Federal Register / Vol. 90, No. 6 / Friday, January 10, 2025 / Notices 2003 

1The Health Insurance Marketplace® is a 

registered service mark of the U.S. Department of 

Health and Human Services. 

are subject to change as priorities 

dictate. For more information on the 

meeting agenda, visit https://

www.cdc.gov/acip/meetings/index.html. 

Meeting Information: The meeting 

will be webcast live via the World Wide 

Web. For more information on ACIP, 

please visit the ACIP website: https://

www.cdc.gov/acip. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials, are part of 

the public record and are subject to 

public disclosure. Comments will be 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

CDC will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near-duplicate examples of a mass-mail 

campaign. CDC will carefully consider 

all comments submitted into the docket. 

Written Public Comment: The docket 

will be opened to receive written 

comments February 3–17, 2025. Written 

comments must be received by February 

17, 2025. 

Oral Public Comment: This meeting 

will include time for members of the 

public to make an oral comment. Oral 

public comment will occur before any 

scheduled votes, including all votes 

relevant to the ACIP’s Affordable Care 

Act and Vaccines for Children Program 

roles. Priority will be given to 

individuals who submit a request to 

make an oral public comment before the 

meeting according to the procedures 

below. 

Procedure for Oral Public Comment: 

All persons interested in making an oral 

public comment at the February 26–28, 

2025, ACIP meeting must submit a 

request at https://www.cdc.gov/acip/ 

meetings/index.html between February 

3–17, 2025, and no later than 11:59 

p.m., EST, February 17, 2025 according 

to the instructions provided. 

If the number of persons requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

time, CDC will conduct a random draw 

to determine the speakers for the 

scheduled public comment session. 

CDC staff will notify individuals 

regarding their request to speak by email 

by February 19, 2025. To accommodate 

the significant interest in participation 

in the oral public comment session of 

ACIP meetings, each speaker will be 

limited to three minutes, and each 

speaker may speak only once per 

meeting. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2025–00349 Filed 1–8–25; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–7077–N] 

Announcement of the Advisory Panel 

on Outreach and Education (APOE) 

Virtual Meeting 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), Health and 

Human Services (HHS). 

ACTION: Notice. 

SUMMARY: This notice announces the 

next meeting of the Advisory Panel on 

Outreach and Education (APOE) (the 

Panel) in accordance with the Federal 

Advisory Committee Act. The Panel 

advises and makes recommendations to 

the Secretary of the U.S. Department of 

Health and Human Services (HHS) (the 

Secretary) and the Administrator of the 

Centers for Medicare & Medicaid 

Services (CMS) on opportunities to 

enhance the effectiveness of consumer 

education strategies concerning the 

Health Insurance Marketplace®,1

Medicare, Medicaid, and the Children’s 

Health Insurance Program (CHIP). This 

meeting is open to the public. 

DATES: 

Meeting Date: Thursday, February 6, 

2025 from 12:30 p.m. to 5 p.m. eastern 

standard time (e.s.t). 

Deadline for Meeting Registration, 

Presentations, Special 

Accommodations, and Comments: 

Thursday, January 23, 2025 by 5 p.m. 

e.s.t. 

ADDRESSES: 

Meeting Location: Virtual. All those 

who RSVP will receive the link to 

attend. 

Presentations and Written Comments: 

Presentations and written comments 

should be submitted to: Hailey Gutzmer, 

Acting Designated Federal Official 

(DFO), Office of Communications, 

Centers for Medicare & Medicaid 

Services, 200 Independence Avenue 

SW, Mailstop 315D.02, Washington, DC 

20201, 410–786–1307, or via email at 

APOE@cms.hhs.gov. 

Registration: Persons wishing to 

attend this meeting must register at the 

website https://CMS-APOEFebruary2025.rsvpify.com or by 

contacting the DFO listed in the FOR

FURTHER INFORMATION CONTACT section of 

this notice, by the date listed in the 

DATES section of this notice. Individuals 

requiring sign language interpretation or 

other special accommodations should 

contact the DFO at the address listed in 

the ADDRESSES section of this notice by 

the date listed in the DATES section of 

this notice. 

FOR FURTHER INFORMATION CONTACT: 

Hailey Gutzmer, Acting Designated 

Federal Official, Office of 

Communications, Centers for Medicare 

& Medicaid Services, 200 Independence 

Avenue SW, Mailstop 315D.02, 

Washington, DC 20201, 410–786–1307, 

or via email at APOE@cms.hhs.gov. 

Additional information about the 

APOE is available at: https://

www.cms.gov/Regulations-andGuidance/Guidance/FACA/APOE. Press 

inquiries are handled through the CMS 

Press Office at (202) 690–6145. 

SUPPLEMENTARY INFORMATION: 

I. Background and Charter Renewal 

Information 

A. Background 

The Advisory Panel on Outreach and 

Education (APOE) (the Panel) is 

governed by the provisions of the 

Federal Advisory Committee Act 

(FACA) (Pub. L. 92–463), as amended (5 

U.S.C. Appendix 2), which sets forth 

standards for the formation and use of 

federal advisory committees. The Panel 

is authorized by section 1114(f) of the 

Social Security Act (the Act) (42 U.S.C. 

1314(f)) and section 222 of the Public 

Health Service Act (42 U.S.C. 217a). 


khammond on DSK9W7S144PROD with NOTICES